Barclays PLC Has $1.11 Million Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

Barclays PLC boosted its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 88.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 83,567 shares of the biotechnology company's stock after purchasing an additional 39,267 shares during the period. Barclays PLC owned about 0.27% of AnaptysBio worth $1,107,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Aristides Capital LLC purchased a new position in shares of AnaptysBio during the 4th quarter valued at $168,000. Russell Investments Group Ltd. increased its position in AnaptysBio by 1,585.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of AnaptysBio by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock worth $6,444,000 after purchasing an additional 21,196 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of AnaptysBio by 240.6% during the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company's stock valued at $1,522,000 after buying an additional 81,195 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of AnaptysBio by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after buying an additional 143,584 shares in the last quarter.

AnaptysBio Stock Down 2.5 %

NASDAQ:ANAB traded down $0.51 during trading hours on Wednesday, hitting $19.61. 710,737 shares of the stock were exchanged, compared to its average volume of 594,865. The company has a market capitalization of $579.92 million, a P/E ratio of -3.23 and a beta of -0.20. The company's 50 day moving average is $18.39 and its two-hundred day moving average is $18.92. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.30) by $0.02. The business had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities research analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has initiated a share repurchase plan on Monday, March 24th that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. HC Wainwright reiterated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research report on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a report on Thursday, May 1st. Wells Fargo & Company raised their target price on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Finally, Wolfe Research initiated coverage on shares of AnaptysBio in a report on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price target on the stock. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $35.88.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.